Related Experiment Video
Updated: Dec 17, 2025
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Recent developments in neoantigen-based cancer vaccines
Kenneth Hodge1, Suangson Supabphol1, Pramod Kumar2
1The Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Abstract:
Cynics point out that a cure for cancer has been "around the corner" for the last 50 years. Nevertheless, the recent convergence of deep DNA, RNA, and proteomic technologies with enhanced understanding of the nuances of the adaptive immune system has generated great optimism amongst researchers. The extraordinary heterogeneity of various cancers, once thought to be a major therapeutic hurdle, may now be bypassed via "personalized" vaccine treatments. Specifically, these treatments involve the identification of MHC-bound peptides that are unique to a patient's cancer (neoantigens), followed by immunization with peptides, RNA, or DNA that encodes these neoantigens via various delivery systems, thus amplifying the immune system's response to the particular cancer. Such approaches have shown dramatic results in animal studies. Not surprisingly, then, the field of neoantigen-based immunotherapy has advanced at a spectacular rate, necessitating that interested individuals stay apprised of recent developments. Following an introduction to the subject, we thus focus on aspects that are particularly fast-moving; the cellular sources of neoantigens, which are surprisingly diverse, the tools that are used for their identification, and the status of the numerous clinical trials that are now being conducted.
Insights
Personalized cancer vaccines targeting unique tumor neoantigens show promise. By identifying and immunizing with cancer-specific peptides, this approach amplifies the immune response, offering new hope in cancer treatment.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Cancer research has long sought effective treatments, facing challenges from tumor heterogeneity.
- Recent advances in DNA, RNA, and proteomic technologies offer new therapeutic avenues.
- Understanding the adaptive immune system is crucial for developing novel cancer therapies.
Purpose of the Study:
- To review the rapidly advancing field of neoantigen-based cancer immunotherapy.
- To highlight the potential of personalized vaccines in overcoming cancer heterogeneity.
- To provide an overview of current research and clinical trial developments.
Main Methods:
- Identification of patient-specific cancer neoantigens (MHC-bound peptides).
- Development of personalized vaccines using peptides, RNA, or DNA encoding neoantigens.
- Utilizing various delivery systems to enhance immune response.
Main Results:
- Neoantigen-based immunotherapy has demonstrated significant success in preclinical animal studies.
- Personalized vaccine strategies show potential to bypass tumor heterogeneity.
- The field is rapidly progressing with numerous ongoing clinical trials.
Conclusions:
- Neoantigen-based immunotherapy represents a promising frontier in personalized cancer treatment.
- Advances in technology and immunology are driving rapid progress in this field.
- Ongoing clinical trials are critical for evaluating the efficacy and safety of these novel therapies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...